Immunogenicity of the novel glucagon analog dasiglucagon: Results of a dedicated immunogenicity trial in type 1 diabetes
- Resource Type
- Authors
- Oren Steen; Thomas R. Pieber; Lone Eske Hansen; Ramin Tehranchi; Olubukola Ajala; Dominik Dahl
- Source
- Diabetes Technology & Therapeutics.
- Subject
- Blood Glucose
Type 1 diabetes
business.industry
Endocrinology, Diabetes and Metabolism
Immunogenicity
macromolecular substances
Pharmacology
Glucagon
medicine.disease
Severe hypoglycemia
Hypoglycemia
Rescue treatment
law.invention
Medical Laboratory Technology
Diabetes Mellitus, Type 1
Endocrinology
Double-Blind Method
Randomized controlled trial
law
Diabetes mellitus
medicine
Humans
business
- Language
- ISSN
- 1557-8593
1520-9156
Dasiglucagon is a next-generation glucagon analogue that is stable in aqueous formulation. This dedicated immunogenicity trial to support use as rescue treatment for severe hypoglycemia was conducted to evaluate the immunogenicity of repeated subcutaneous doses of dasiglucagon in subjects with type 1 diabetes. A total of 112 subjects were randomized 1:1 to receive three subcutaneous weekly doses of either 0.6 mg dasiglucagon or 1.0 mg recombinant glucagon (GlucaGen